<DOC>
	<DOC>NCT01941615</DOC>
	<brief_summary>Investigate the effect of multiple oral doses of BI 207127 + faldaprevir (FDV) on the multiple dose pharmacokinetics of ethinylestradiol and levonorgestrel (MicrogynonÂ®) in healthy premenopausal female volunteers.</brief_summary>
	<brief_title>Effect of BI 207127 + Faldaprevir on Blood Levels of Oral Contraceptives Containing Ethinylestradiol and Levonorgestrel</brief_title>
	<detailed_description />
	<mesh_term>Levonorgestrel</mesh_term>
	<mesh_term>Ethinyl estradiol, levonorgestrel drug combination</mesh_term>
	<mesh_term>Ethinyl Estradiol-Norgestrel Combination</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<criteria>Inclusion criteria: Healthy female subjects Age 18 to 35 years (inclusive) Body Mass Index 2029.9 kg/m2 Use of hormonal contraception (i.e. oral contraceptives, hormonal contraceptive vaginal ring, but not hormonecontaining intrauterine devices, depot injections or contraceptive implants) Exclusion criteria: Any relevant deviation from healthy conditions Subject is assessed by the investigator as unsuitable for inclusion, for instance, because considered not able to understand and comply with study requirements, or has a condition that would not allow safe participation in the study Positive pregnancy test, pregnancy or planning to become pregnant within 1 month of study completion, or lactation Any relevant finding of the gynaecological examination Thrombotic predisposition according to thrombophilic testing Existing or history of arterial thrombotic or embolic processes, conditions which predispose to them e.g. disorders of the clotting processes, valvular heart disease and atrial fibrillation Existing or history of confirmed venous thromboembolism, family history of venous thromboembolism, and other known risk factors for venous thromboembolism. Relevant varicosis No use of an additional contraceptive method from screening examination until 1 month after last study drug administration (acceptable methods are considered to be barrier methods, sexual abstinence, nonhormonecontaining intrauterine device, or vasectomisation for the male partner). Use of hormonecontaining intrauterine device, depot injection or contraceptive implants Any history of relevant liver diseases (e.g. disturbances of liver function, jaundice or persistent itching during a previous pregnancy, DubinJohnson syndrome, Rotor syndrome, or previous or existing liver tumours) AST (aspartate transaminase) and/or ALT (alanine transaminase) &gt; 1.5 ULN (upper limit of normal)</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>